Bodolf Hareide, MD, was the general director of the National Institute of Public Health (NIPH) during the crucial years when MoBa was planned and initiated. The following paragraphs are excerpts from a meeting between Hareide and the guest editors of this issue.
The National Institute of Public Health (NIPH) was established in 1929. At that time, combatting diseases caused by microorganisms was the main task. The institute was the national microbiology laboratory. It also developed expertise on blood typing, and performed research in immunology and vaccine development. For decades, infectious disease control was the primary activity. From the 1970s, changes took place. The hospitals expanded with more academic staff and took responsibility for patient-oriented diagnostic laboratory procedures. This changed the scientific landscape and the duties of the NIPH. The Institute continued to work with infections and vaccines, but also established toxicology as a major discipline, and later set up departments of health services research and epidemiology.
The use of the assumed harmless drug thalidomide among pregnant women caused birth defects in children in the 1960s. This called for surveillance of congenital malformations and was a major reason for establishing the Medical Birth Registry of Norway (MBRN) in 1967. There was much debate on the governance and localization of the registry. A committee led by Hareide concluded that the registry should be located in affiliation with the University of Bergen. Many decades later, when NIPH reorganized in 2002 and became the Norwegian Institute of Public Health, MBRN became an integrated part of NIPH, still located in Bergen, based on a recommendation by another Hareide committee. The fusion made NIPH responsible for the management of the registry.
Hareide started his career at NIPH in 1981. In 1984, when Christian Lerche left the position, Hareide was appointed the new general director. During the 1980s, a white paper on NIPH's national obligations to promote public health was discussed in Parliament. Afterwards, NIPH stopped performing routine diagnostic tests and became an institution that had general research in disease prevention as a major activity. This shift meant reallocation of resources and personnel, and gave Hareide the flexibility to establish new activities. Child health became an important area for research.
There was close collaboration between researchers in Oslo (NIPH) and Bergen (MBRN) in the early planning of what was originally called "the Newborn Cohort", later "Better Health for Mother and Child" and finally "the Norwegian Mother and Child Cohort Study". It was not always easy to agree on positions and the use of personnel and resources. To promote decision making, Hareide appointed a steering committee consisting of researchers from both cities. The committee was led by Hareide. All issues and challenging resolutions were broadly discussed and considered scientifically before decisions were made. Even though many stakeholders and research groups were skeptical to such a big research project, the good collaboration with scientists in Bergen paved the way for establishing the cohort with a main goal of finding new causes of diseases, aiming at prevention. Thus, Stein Emil Vollset and Rolv Terje Lie in the early 1990s prepared the first version of the protocol of the study based on recruitment of the women through the general practitioners.
External expert groups were set up to ensure that the study was conducted by high ethical standards, and that all stakeholders were heard in the initial phases. These expert panels did not meet often, and they were mainly important for discussion about the recruitment part. This was also the case for the external group with focus on the ethical aspects. The broad expertise at the NIPH was an important support in planning the study more generally.
Leiv Sigmund Bakketeig was the first principal investigator in the 1990s. After many meetings with the Data Inspectorate, the study obtained its approval in 1996. The pilot started in the island of Sotra on the Western coast of Norway. The pilot study was successful, but the Medical Association of General Practitioners raised concerns about the study. As a consequence, the Minister of Health announced that the study had to be put on hold until it had been discussed in Parliament in 1998 which was potentially troublesome for NIPH as the study had not been mentioned earlier in the correspondence between NIPH and the Ministry of Health. Furthermore, the study had not been included in the financial allocations to the NIPH. However, this did not become an issue in the discussions, and the Parliament voted for the approval of the study and granted one million NOK annually. This was a clear message that we should continue. During this summer, Bakketeig was offered a position as a professor of epidemiology at the
